Spinal administration of morphine for laparoscopic pancreatic surgery : A double blind, propspective randomized placebo-controlled trial.
- Conditions
- postoperative pain treatment after minimally invasive pancreatic surgeryTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
- Registration Number
- EUCTR2021-002625-20-BE
- Lead Sponsor
- niversity Hospitals Leuven
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 128
- 18-80 years of age
-BMI = 40 kg/m2
-Patient is able to give informed consent
-Patient understands the use of morphine PCIA
-Patient is scheduled for elective minimally invasive pancreatic surgery
-ASA I-IV
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 64
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 64
- Refusal to participate in the trial
-Inability to operate a PCIA system
-Chronic opioid use, or chronic pain patient
-Obstructive sleep apnea syndrome (OSAS) requiring CPAP therapy
-If patient is known with kidney disease or renal dysfunction, the GFR will be checked and patient will be excluded if GFR < 30 mL/min.
-Neuraxial anesthesia will only be performed with normal clotting lab results (UZ Leuven):
-Thrombocytes = 80 x 109/L
-INR = 1,5
-aPTT (s) = 31
-Presence of contra-indications for spinal anesthesia (patients on anticoagulants, coagulation deficits, severe spinal canal stenosis, neurological deficits, increased intracranial pressure, severe aortic stenosis as defined by aortic valve area (AVA) < 1 cm2)
-Presence of contra-indications for intrathecal medication (pre-operative respiratory oxygen need, sleep apnea disorder, diamorphine/morphine allergy, local anesthetic allergy)
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To test the efficacy of intrathecal morphine after minimally invasive pancreatic surgery;Secondary Objective: not applicable;Primary end point(s): -Cumulative 24-hour morphine consumption post-surgery. ;Timepoint(s) of evaluation of this end point: 24 hours after start PCIA
- Secondary Outcome Measures
Name Time Method